- Short communication
- Open Access
Image quality and quantification accuracy dependence on patient body mass in 89Zr PET/CT imaging
EJNMMI Physics volume 8, Article number: 72 (2021)
This study was conducted to clarify how patient body mass affects the image quality and quantification accuracy of images obtained using 89Zr PET/CT. 89Zr PET/CT images from time-of-flight (TOF) PET/CT and semiconductor (SC) PET/CT were obtained using three types (M, L, LL; corresponding to increasing patient body weight) of custom-made body phantoms designed similarly to the National Electrical Manufacturers Association (NEMA) IEC body phantom. The phantom data were analyzed visually and quantitatively to derive image quality metrics, namely detectability of the 10-mm-diameter hot sphere, percent contrast for the 10-mm-diameter hot sphere (QH,10 mm), percent background variability (N10mm), contrast-to-noise ratio (QH,10 mm/N10mm), and coefficient of variation of the background area (CVBG).
Visual assessment revealed that all the 10-mm-diameter hot spheres of the three types of phantoms were identifiable on both SC and TOF PET/CT images. The N10mm and CVBG values were within the proposed reference levels, and decreased with acquisition duration for both PET/CT types. At 10-min acquisition, the QH,10 mm/N10mm of SC PET/CT was greater than the proposed reference level in all phantoms. However, the QH,10 mm/N10mm of TOF PET/CT was greater than the proposed reference level in M-type phantom alone. All the SUVBG values were within 1.00 ± 0.05 for both PET/CT types.
This study showed that the image quality and quantification accuracy depend on the patient’s body mass, suggesting that acquisition time on 89Zr PET/CT should be changed according to the patient’s body mass.
The positron radionucleotide 89Zr has been utilized for PET imaging labeled monoclonal antibodies to date, because long half-life radioisotope is needed for assessment of the circulating probes. 89Zr facilitates high-resolved PET imaging with a short positron range by emitting low-energy β+ rays. After introduction of desferrioxamine B (DFO) as specific chelator for 89Zr labeling, the number of antibodies and antibody fragments have been approved by the Food and Drug Administration (FDA) for last decade. Over the 17 antibodies including trastuzumab, bevacizumab, cetuximab, and rituximab were labeled with 89Zr for PET imaging [1,2,3,4,5]. Evaluating the target status of tumors is crucial for clinical decision making for patients planning molecular targeting therapy. A whole-body evaluation of target expression with 89Zr-trastuzumab PET changes the treatment plan . Based on the results from recent two publications, the authors demonstrated that 89Zr-trastuzumab reflects tumor heterogeneity and supports clinical decision making when HER2 status could not be determined by standard procedures, which allows the selection of a personalized therapy [7, 8]. Thus, 89Zr-monoclonal antibody PET is promising for evaluating patient selection and therapeutic effect.
89Zr-monoclonal antibody PET would be utilized for clinical trials of multicenter in the near future. Thus, standardization and harmonization of 89Zr PET/CT have been investigated to date. According to the EANM procedure guideline for tumor imaging: version 2.0, EARL accreditation enhances the quality standards of PET/CT investigations to minimize the technical factors and ensures performance of PET/CT machines by harmonization . EARL has also 89Zr PET/CT accreditation to ensure quantitative image quality using 89Zr labeled pharmaceuticals. In this context, several investigators have addressed multicenter harmonization of 89Zr PET/CT to ensure image quality and quantitation accuracy [10,11,12,13]. However, the results of the previous studies did not contain the problems affected by the patient’s body mass. PET imaging of larger patients is affected by high noise levels, because of the considerable intrinsic attenuation.
The purpose of this study was to clarify how patient body mass affects the image quality and quantification accuracy of images obtained using 89Zr PET/CT.
Two PET/CT machines (Celesteion, time-of-flight [TOF] PET/CT and Cartesion Prime, semi-conductor [SC] PET/CT, Canon Medical Systems, Otawara, Tochigi, Japan) were investigated for study. The SC PET/CT is equipped with a silicon photomultiplier (SiPM). Three types of body phantoms including 30 (M type), 33 (L type), and 36 (LL type) cm in the major axis, corresponding to 60 kg, 80 kg, and 100 kg body weight, respectively, were designed similarly to National Electrical Manufacturers Association (NEMA) IEC body phantom by custom made (Fig. 1). These phantoms contained six spheres with inner diameters of 10, 13, 17, 22, 28, and 37 mm. All spheres were filled with 89Zr solutions to achieve 10:1 sphere-to-background activity concentration ratio based on the prior study of international standardization . This study did not include human data and personal information.
The phantoms underwent a low-dose CT acquisition with auto-exposure of an X-ray tube current followed by PET acquisition for each scan. A 20-min-per-bed-position 1-bed-position for list mode acquisition and 5-, 10-, and 15-min-per-bed-position 2-bed-position acquisition were subsequently obtained for three types of phantoms (Fig. 2). PET images of SC PET/CT were reconstructed using parameters featuring ordered subset expectation maximization (OSEM) into a 336 × 336 matrix; voxel size 9.44 μl (2.11 × 2.11 × 2.11 mm) with two iterations, 12 subsets, a 3.0-mm 3D Gaussian filter, and active corrections by CT-based attenuation, scatter, TOF, and point-spread function (PSF). PET images of TOF PET/CT were also reconstructed using parameters featuring OSEM into a 336 × 336 matrix; voxel size 8.47 μl (2.04 × 2.04 × 2.04 mm) with three iterations, 10 subsets, a 6.0-mm 3D Gaussian filter, and corrections by CT-based attenuation, scatter, TOF, and PSF. Reconstructed images were evaluated by quantitative methods. Image analysis was performed using RAVAT (Nihon Medi-Physics Co., Ltd.) .
Detectability of the 10-mm-diameter hot sphere was visually assessed by three nuclear medicine technologists in a three-step scale (0, not visualized; 1, visualized, but similar hot spots are observed; and 2, identifiable). The VOX-BASE/MANAGER (J-MAC SYSTEM, INC., Japan) was used to display PET images using an invert gray scale with an upper level of 10 and a lower level of 0 (SUV-scaled).
Quantitative analysis of image quality was performed for each image in accordance with the guidelines of the Japanese Society of Nuclear Medicine (JSNM) . The percent contrast for the 10-mm hot sphere (QH,10 mm), the percent background variability (N10mm) for the 10-mm circular region-of-interest (ROI), QH,10 mm/N10mm ratio, and the coefficient of variation on the background area (CVBG) (image noise level) were calculated. The background standardized uptake value (SUVBG), which reflects the accuracy of the calibration, was evaluated by the average value of SUV calculated by 12 ROIs with a diameter of 37 mm placed in the BG region, also in accordance with the guidelines of the JSNM . The recovery coefficient (RC) of all hot spheres was quantified using RCmax and RCpeak (according to the QIBA calculation algorithm) as indicators as shown in Eq. 1 and Eq. 2 [14, 15]. Based on EARL accreditation manual Ver 2.0, the calibration quality control for 89Zr is similar to the 18F calibration phantom procedure, because 89Zr RCs are directly related to the RCs obtained with 18F [10, 12].
Differences between groups for quantification data were analyzed using the parametric Student t test. A P value < 0.05 was considered significant. Statistical analysis was performed using SPSS version 28.0 (IBM-SPSS Japan Inc, Tokyo, Japan).
Visual assessment by SC PET/CT showed that all the 10-mm-diameter hot sphere were identifiable (Fig. 2). In contrast, detectability of the 10-mm-diameter hot sphere depended on scan duration in L type and LL type phantoms on TOF PET/CT. All the 10-mm-diameter hot sphere of three types of phantoms were visually identifiable on both PET/CT. The QH,10 mm, N10mm, QH,10 mm/N10mm, and CVBG as a function of scan duration in all phantoms are shown in Fig. 3. The QH,10 mm did not correlate with acquisition duration. For N10mm, significant differences were observed in the 10-mm-sphere-detectable values among the three types of phantoms. The N10mm and CVBG decreased with acquisition duration for both PET/CT. The QH,10 mm/N10mm increased mostly with acquisition duration. SC PET/CT was capable of showing enough QH,10 mm/N10mm greater than 2.8 except for LL type phantom with 5-min acquisition. However, the QH,10 mm/N10mm of TOF PET/CT at 5-min acquisition was less than 2.8 in all phantoms. At 10-min acquisition, the QH,10 mm/N10mm of SC PET/CT was greater than 2.8 in all phantoms, whereas the QH,10 mm/N10mm of TOF PET/CT was greater than 2.8 in M type phantom alone. All QH,10 mm/N10mm at 15-min acquisition were greater than 2.8 in all phantoms for both of SC PET/CT and TOF-PET/CT.
The SUVBG of both scanners in three types of phantoms is shown in Fig. 4. The SUVBG tended to be greater depending on phantom size. All the SUVBG were within 1.00 ± 0.05 for both PET/CT. For TOF PET/CT, mean SUV of LL type was significantly greater than those of M type (p = 0.0085) or L type (p = 0.0092). Meanwhile, for SC PET/CT, mean SUV of LL type was significantly greater than those of M type (p = 0.0038). However, no significant difference was found in mean SUV obtained by SC PET/CT between L type and M type, or LL type and L type. The relationship between RCmax or RCpeak and sphere diameter is shown in Fig. 5. Both of the RCmax and RCpeak of L type were the highest, but the differences were not statistically significant. The RCmax was affected by statistical noise for both PET/CT, while the RCpeak was stable and robust for statistical noise. However, RC peak is susceptible to underestimation of quantitative value due to partial volume effect.
The purpose of this study was to investigate whether the image quality and quantification accuracy were affected by the patient’s body mass on 89Zr PET/CT. Expectedly, we found that 10-mm-diameter hot sphere could be detected for 5-min acquisition by both SC PET/CT and TOF-PET/CT. However, the detectability depended on PET/CT machines to a similar degree in all types of phantoms.
The N10mm reflects background variability, and all the N10mm examined in our study is greater than the proposed reference level. The technique of PSF and TOF contribute to improving contrast in the 10-mm-diameter hot sphere and resulted in increased background variability. The QH,10 mm/N10mm assures 10-mm-diameter hot sphere visibility, but this metric depends on type of PET/CT scanner models and acquisition duration. In our study, the SC PET/CT showed enough QH,10 mm/N10mm greater than the proposed reference level except for LL phantom with 5-min acquisition. However, the QH,10 mm/N10mm of TOF PET/CT was mostly less than the proposed reference level at 5- or 10-min acquisition in all phantoms. The QH,10 mm/N10mm implies information of the 10-mm-diameter hot sphere contrast and the background variability, and the balance of contrast and noise is valuable for visual detectability of small hot lesion. In this context, long scan duration would be required for TOF PET/CT. All the CVBG calculated in our study were greater than the proposed reference level and decreased with acquisition duration for both PET/CT. The CVBG is reproducible metric and has been used for standardization of 18FDG PET/CT in oncology [16,17,18,19,20]. The use of CVBG might facilitate international standardization to reduce variability and global 89Zr PET/CT studies . However, the CVBG cannot reflect the effective spatial resolution of the scanner as directly as the RCmax or RCpeak. Both metrics are recommended to standardization on 89Zr PET/CT.
In our study, we found that TOF PET/CT was capable of enough detectability by 10-min acquisition per bed position when scanning patient of middle-sized body mass. However, when we scan patient of large-sized body mass, at least 15-min acquisition per bed position would be preferable. In contrast, our findings that 5-min acquisition per bed position by SC PET/CT represented enough detectability when scanning patient of middle-sized body mass. It should be highlighted that SC PET/CT machine is adequate for whole-body scan of 89Zr PET/CT. Nevertheless, when we scan patient of large-sized body mass, at least 10-min acquisition per bed position is required.
Our study showed that the image quality and quantification accuracy was affected by the patient’s body mass on 89Zr PET/CT. These results were mirrored to the previous results of 18F-FDG PET/CT. The main differences between 18F and 89Zr are the practical range of positron provided by 18F and 89Zr and cascade γ-ray (909 keV) from each isotope. How these two issue affect image quality was not fully elucidated, but our results revealed that affection to detectability and accuracy were clinically limited.
Both of the RCmax and RCpeak of L type were the highest among all phantoms, but the differences were not statistically significant. The precise reason why the L type showed the highest values was unclear, but it may be due to large contribution of noise specific to the L type, or inaccurate alignment of the 10-mm hot sphere to the slice center. These can be verified by further multiple re-examinations.
Kaalep and the colleagues suggested that RC curves derived from 89Zr phantom using quantitative metrics of RCmax and RCpeak resulted in increased variability possibly due to activity measurement and phantom filling procedures . This observation is in agreement with our results, because when we investigated both of SC PET/CT and TOF PET/CT, we observed that there was variable bias in the relationship between RCmax or RCpeak and sphere diameter. Moreover, we observed that RCpeak showed variable bias minimally was similar to the results of the previous study using calibration QC and NEMA phantom QC (12). Altogether, the observation discussed above indicate that RCpeak is suggestive metric for data comparison among PET/CT systems.
We demonstrated effects of patient body mass on image quality and quantification accuracy of images obtained using 89Zr PET/CT, indicating that acquisition time should be changed according to the patient’s body mass. The RCpeak shows minimal variability compared to RCmax on 89Zr PET/CT, but the underlying precise mechanism of this evidence is unknown. Further investigation is required to clarify optimal metrics for comparison among PET/CT systems.
Availability of data and materials
Verel I, Visser GW, van Dongen GA. The promise of immuno-PET in radioimmunotherapy. J Nucl Med. 2005;46(suppl):164S-171S.
Zalutsky MR. Potential of immuno-positron emission tomography for tumor imaging and immunotherapy planning. Clin Cancer Res. 2006;12:1958–60.
Reichert JM. Monoclonal antibodies as innovative therapeutics. Curr Pharm Biotechnol. 2008;9:423–30.
Zhang Y, Hong H, Cai W. PET tracers based on zirconium-89. Curr Radiopharm. 2011;4:131–9.
Verhoeff SR, van Es SC, Boon E, van Helden E, et al. Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2019;46:1931–9.
Dijkers EC, Kosterink JG, Rademaker AP, et al. Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med. 2009;50:974–81.
Bensch F, Brouwers AH, Lub-de Hooge MN, de Jong JR, van der Vegt B, Sleijfer S, et al. (89)Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up. Eur J Nucl Med Mol Imaging. 2018;45(13):2300–6.
Gebhart G, Lamberts LE, Wimana Z, Garcia C, Emonts P, Ameye L, et al. Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. Ann Oncol. 2016;27(4):619–24.
Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2014;42:328–54.
Makris NE, Boellaard R, Visser EP, et al. Multicenter harmonization of 89Zr PET/CT performance. J Nucl Med. 2014;55:264–7.
Soderlund AT, Chaal J, Tjio G, et al. Beyond 18F-FDG: characterization of PET/CT and PET/MR scanners for a comprehensive set of positron emitters of growing application—18F, 11C, 89Zr, 124I, 68Ga and 90Y. J Nucl Med. 2015;56:1285–91.
Kaalep A, Huisman M, Sera T, et al. Feasibility of PET/CT system performance harmonisation for quantitative multicentre 89Zr studies. EJNMMI Phys. 2018;5:26.
Christian PE, Williams SP, Burrell L, et al. Optimization of 89Zr PET imaging for improved multisite quantification and lesion detection using an anthropomorphic phantom. J Nucl Med Technol. 2020;48:54–7.
Daisaki H, Kitajima K, Nakajo M, et al. Usefulness of semi-automatic harmonization strategy of standardized uptake values for multicenter PET studies. Sci Rep. 2021;11:8517.
Fukukita H, Suzuki K, Matsumoto K, et al. Japanese guideline for the oncology FDG-PET/CT data acquisition protocol: synopsis of Version 20. Ann Nucl Med. 2014;28(7):693–705.
Kinahan P, Wahl R, Shao L, Frank R, Perlman E. The QIBA profile for quantitative FDG-PET/CT oncology imaging. J Nucl Med. 2014;55:1520.
QIBA-PET/CT. QIBA Profile FDG-PET/CT as an Imaging Biomarker Measuring Response to Cancer Therapy. Radiol Soc North Am. 2016:75.
Westerterp M, Pruim J, Oyen W, et al. Quantification of FDG PET studies using standardised uptake values in multi-centre trials: effects of image reconstruction, resolution and ROI definition parameters. Eur J Nucl Med Mol Imaging. 2007;34:392–404.
Sunderland JJ, Christian PE. Quantitative PET/CT scanner performance characterization based upon the Society of nuclear medicine and molecular imaging clinical trials network oncology clinical simulator phantom. J Nucl Med. 2015;56:145–52.
Kaalep A, Sera T, Rijnsdorp S, et al. Feasibility of state of the art PET/CT systems performance harmonisation. Eur J Nucl Med Mol Imaging. 2018;45(8):1344–61.
Jauw YWS, Heijtel DF, Zijlstra JM, et al. Noise-induced variability of immuno-PET with zirconium-89-labeled antibodies: an analysis based on count-reduced clinical images. Mol Imaging Biol. 2018;20:1025–34.
The authors thank the staff of Telix Pharmaceuticals Japan for technical support. The authors also thank Guideline Committee of Japan Radiological Society (JRS) for their vulnerable assistance in edit of manuscript and for their helpful suggestions. We have also been given helpful suggestions by Daniel C Sullivan, MD and Alexander Guimaraes, MD, Steering Committee, Quantitative Imaging Biomarkers Alliance (QIBA), Radiological Society of North America (RSNA) and Shigeki Aoki, MD, Chair of Steering Committee, J-QIBA, JRS.
None of the authors has a financial relationship with a commercial entity that has an interest in the subject of this article.
Ethics approval and consent to participate
This study does not contain any studies with human participants or animals performed by any of the authors.
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Tateishi, U., Daisaki, H., Tsuchiya, J. et al. Image quality and quantification accuracy dependence on patient body mass in 89Zr PET/CT imaging. EJNMMI Phys 8, 72 (2021). https://doi.org/10.1186/s40658-021-00420-4
- Patient’s body mass